Lv1
100 积分 2024-04-11 加入
Safety and clinical efficacy of IOA-289, a novel autotaxin inhibitor, plus gemcitabine and nab-paclitaxel (GnP) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC)
3天前
已完结
[Retrospectively analysis of characteristics and risk factors of immune treatment-related hepatic adverse events in malignant tumor]
6个月前
已完结
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
6个月前
已完结
Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer
9个月前
已完结
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
9个月前
已完结
Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations
9个月前
已完结
c‐Met inhibition enhances chemosensitivity of human ovarian cancer cells
10个月前
已完结
皖公网安备34019202002308
